In short
Clinical trials investigating IHMA-2121771-2 are studying treatment in people with cystic fibrosis and chronic Pseudomonas lung infection. The trial data focus on whether the study treatment can improve infection burden and how it performs in a randomized, double-blind phase 2 study.
Key points
- Clinical trial data for IHMA-2121771-2 show one completed phase 2 study in people with cystic fibrosis and chronic Pseudomonas lung infection. The study was randomized and double-blind, which helps make the results more reliable. It compared BX004 inhalation with placebo in 63 participants. The main outcome measured change in Pseudomonas levels in sputum after 8 weeks of treatment. This means the trial focused on whether the study treatment could reduce the amount of bacteria in the lungs.
Trial overview
The available trial for IHMA-2121771-2 is a phase 2 study in people with cystic fibrosis and chronic Pseudomonas lung infection. The study title describes it as a randomized, double-blind study, and the brief summary says it looked at the effect of nebulized BX004 on sputum Pseudomonas burden.
Who participated
The target population was people with cystic fibrosis and chronic Pseudomonas pulmonary infection. Pulmonary infection means infection in the lungs, and chronic means it lasts a long time. The trial enrolled 63 participants.
Study design and phase
This was an interventional study, which means researchers gave a treatment and then measured the results. It was randomized, so participants were assigned by chance to a study group. It was also double-blind, meaning the participants and study team did not know who received BX004 or placebo during the study.
The study compared BX004 given by inhalation with BX004 placebo. A placebo is a look-alike treatment used to help show whether the study treatment makes a difference.
What was measured
The main endpoint was the change from baseline in PsA CFU/g of sputum at 8 weeks of treatment, also called day 57 or end of treatment. Baseline means the starting point before treatment began. PsA CFU/g is a lab measure of how much Pseudomonas bacteria is found in sputum.
This endpoint shows whether the study aimed to reduce the amount of bacteria in the sputum after treatment. The brief summary states that the study tested the efficacy of nebulized BX004 on sputum PsA burden in subjects with chronic Pseudomonas pulmonary infection.
Trial status and size
The trial status is listed as completed. Completed means the study has finished collecting the planned data. The enrollment was 63 participants, which is a relatively small phase 2 study focused on early evidence of effect.
What the trial helps answer
This trial helps answer whether the study treatment may reduce Pseudomonas burden in the lungs of people with cystic fibrosis. Because it was randomized and double-blind, the design was meant to make the comparison between BX004 and placebo more reliable. The trial does not provide broader drug information beyond the study design, population, and the infection-related outcome it measured.